RAPT Therapeutics Q3 EPS $(0.82) Misses $(0.75) Estimate
Portfolio Pulse from Benzinga Newsdesk
RAPT Therapeutics reported a Q3 EPS loss of $(0.82), missing the consensus estimate of $(0.75) by 9.33%. This represents a 30.16% increase in losses compared to $(0.63) per share in the same quarter last year.
November 13, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RAPT Therapeutics reported a larger-than-expected quarterly loss, missing analyst estimates and showing a significant increase in losses year-over-year.
The reported earnings miss and increased year-over-year losses are likely to negatively impact investor sentiment in the short term, potentially leading to a decrease in RAPT's stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100